Novo Nordisk has dropped its legal case against telehealth provider Hims & Hers over patent infringement, after the two companies agreed Hims would sell Novo’s branded medicines through its platform. “We have decided to drop the current court proceedings and, of course, we reserve to bring that back if need be, but I don’t foresee…
A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership:…
J. David Ake | Getty Images News | Getty Images A series of policy changes in the so-called “big beautiful bill” are undermining the Affordable Care Act marketplace, in ways that may at first seem relatively subtle but which add up to a major change, health policy experts say. That, in turn, has important implications…
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from…
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the…
Two of the largest U.S. gym operators delivered the same headline in their latest earnings reports: strong growth. But beneath the surface, Life Time Group Holdings and Planet Fitness told very different stories about the American consumer. They highlighted a widening divide between higher-income households that continue to spend freely and more price-sensitive consumers who…
Novo Nordisk stock fell 13% Monday after it said its next-generation weight loss drug didn’t meet its key goal of showing that it wasn’t inferior to Eli Lilly’s rival drug. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks,…
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks, announcing new nutrition policies during a press conference at the Department of Health and Human Services in Washington, D.C., U.S., Jan. 8, 2026. Jonathan Ernst | Reuters Secretary of Health and Human Services Robert F. Kennedy Jr. defended President Donald Trump‘s executive order…
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the White House, Nov. 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one — but recent weeks have delivered more…
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty Images CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant’s turnaround plan. “’24 was a tough year for…
